Consistent with previous studies, HDACi-109 treatment of PBMCs increased the median steady-state FXN transcript level to 3.9-fold over the corresponding DMSO control (Figure 1A), indicating that it reactivates the silenced FXN gene in FRDA. This evidence concerns the gene FXN and Friedreich ataxia.